福多司坦治疗慢性阻塞性肺疾病急性加重患者的临床观察

目的: 探讨福多司坦对慢性阻塞性肺疾病急性加重(AECOPD)患者的临床疗效及安全性。方法: 将100例AECOPD患者随机分成治疗组50人及对照组50人,两组均使用广谱抗生素、吸氧、支气管扩张剂等常规治疗, 同时治疗组给予口服福多司坦片 400 mg,每日3次,对照组给予口服盐酸氨溴索片(沐舒坦片)60 mg, 每日3次,观察两组患者的临床症状改善情况及安全性并分析。结果: 治疗组在临床综合疗效评价中总有效率明显优于对照组(P<0.05),而两组在安全性评价比较中无统计学差异(P>0.05)。结论: 福多司坦治疗AECOPD患者临床疗效确切,不良反应轻,值得临床推广。

Clinical observation of fudosteine in the acute exacerbation of chronic obstructive pulmonary disease

AIM: To evaluate the efficacy and safety of fudosteine in the acute exacerbation of chronic obstructive pulmonary disease( AECOPD). METHODS: 100 patients diagnosed as AECOPD were randomly divided into either therapy group and control group. Antibiotics, oxygen, bronchodilators, etc were used in two groups. At the same time the therapy group was given oral fudosteine 400mg three times daily, and the control group was given oral mucosolvan 60mg three times daily. Then the clinical efficacy and safety in two groups of patients were observed and analyzed. RESULTS: The response rate (RR) of clinical composite efficacy in the therapy group was significantly higher than that in the control group (86% vs 68%, P<0.05), and there was no significantly difference between the two groups of the safety (P>0.05). CONCLUSION: Fudosteine tablet is effective and slight side-effect used in AECOPD and should be used as a routine.